• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 3. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 4. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 5. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Latest Research Advances on 956373-21-0 and (1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl(methyl)amine in Chemical Biomedicine

The compound with CAS number 956373-21-0, also known as (1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl(methyl)amine, has recently garnered significant attention in the field of chemical biomedicine due to its unique structural properties and potential therapeutic applications. This research briefing synthesizes the latest findings on this compound, focusing on its synthesis, pharmacological activities, and emerging applications in drug development.

Recent studies have highlighted the compound's role as a versatile intermediate in the synthesis of novel bioactive molecules. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its utility in constructing pyrazole-based scaffolds, which are increasingly important in the development of kinase inhibitors. The ethyl and methyl substitutions at the 1, 3, and 5 positions of the pyrazole ring, combined with the methylamine moiety at the 4-position, create a pharmacophore with excellent bioavailability and target selectivity.

Pharmacological investigations have revealed promising CNS activity associated with 956373-21-0. Research conducted at several academic institutions has shown that derivatives of this compound exhibit significant binding affinity to serotonin and dopamine receptors, suggesting potential applications in neuropsychiatric disorders. Particularly noteworthy is its structural similarity to known psychoactive compounds, though with a markedly improved safety profile in preclinical models.

From a synthetic chemistry perspective, recent advances have optimized the production of 956373-21-0 through novel catalytic methods. A 2024 study in Organic Process Research & Development reported a high-yield (87%), scalable synthesis using palladium-catalyzed amination, representing a significant improvement over previous routes. This development is particularly important for ensuring consistent quality in pharmaceutical applications.

The compound's physicochemical properties have been extensively characterized in recent work. With a calculated logP of 2.1 and good solubility in both aqueous and organic solvents, 956373-21-0 demonstrates excellent drug-like properties. Molecular modeling studies suggest that the compound's conformation allows for optimal interactions with biological targets while maintaining metabolic stability.

Emerging applications in targeted drug delivery systems have been explored in several 2024 publications. The amine functionality of (1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl(methyl)amine serves as an effective conjugation site for antibody-drug conjugates (ADCs) and nanoparticle-based delivery systems. This versatility positions the compound as a valuable building block in next-generation bioconjugate therapeutics.

Safety and toxicology assessments, while still preliminary, indicate a favorable profile for 956373-21-0. In vitro studies show minimal cytotoxicity at therapeutic concentrations, and early in vivo data suggest good tolerability in rodent models. However, comprehensive ADME studies are still needed to fully characterize the compound's pharmacokinetic properties.

The pharmaceutical industry has taken notice of these developments, with several companies filing patents incorporating 956373-21-0 derivatives in their claims. Analyst reports suggest growing commercial interest, particularly in the areas of CNS disorders and oncology applications. Market projections estimate significant growth potential for this chemical class over the next five years.

In conclusion, the current research landscape for 956373-21-0 and its derivatives demonstrates substantial promise across multiple therapeutic areas. The compound's unique structural features, combined with its favorable physicochemical and pharmacological properties, make it an important focus for ongoing drug discovery efforts. Future research directions likely will explore its potential in combination therapies and as a platform for developing novel chemical entities with improved target specificity and reduced off-target effects.

• 1004195-30-5(1-(1-Ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methylpiperazine)
• 514816-08-1(methyl(trimethyl-1H-pyrazol-4-yl)methylamine)
• 956363-88-5(N-(1-ethyl-3-methyl-1H-pyrazol-4-yl)methyl-N-methylamine)
• 898046-26-9((1-Ethyl-5-methyl-1H-pyrazol-4-yl)methylamine)
• 936940-14-6((1-ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methylamine)
• 1015845-57-4(N-(1-Ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methyl-N-(2-methoxyethyl)amine)
• 943106-34-1(N-(1-Ethyl-5-methyl-1H-pyrazol-4-yl)methyl-N-methylamine)
• 956440-75-8(N-(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylethanamine)
• 942852-84-8(N-(1-Ethyl-3,5-dimethyl-1H-pyrazol-4-yl)methylethanamine)
• 1007520-12-8(N,3,5-Trimethyl-1-(1-methylethyl)-1H-pyrazole-4-methanamine)